Table 2.
Engraftment potential and disease expansion
| Sample ID | Primary engraftment (time, wk [range])* | Secondary engraftment | Minimum disease burden†(lymphoblasts × 107) |
|---|---|---|---|
| 96 | Yes (6 [5-6]) | Yes (3 weeks [3-4]) | 264 (212-423) |
| 200 | Yes (6 [4-7]) | Yes (4 weeks [3-6]) | 67 (55-94) |
| 240 | Yes (12 [12]) | Yes (5 weeks [5-6]) | 127 (69-183) |
| 359 | Yes (7 [7]) | Yes (5 weeks [5]) | 134 (74-190) |
| 195 | Yes (12 [12]) | Yes (11 weeks [9-12]) | 70 (data on 1 mouse) |
| 302 | Yes (12 [12]) | Yes (12 weeks [12]) | 20 (10-50) |
| 176 | Yes (12) | ND | Not counted |
| 174 | No | N/A | N/A |
| 331 | No | N/A | N/A |
Time points listed are average time to engraftment followed by range in weeks in brackets.
ND indicates not done; N/A, not applicable.
*
Average time to engraftment [range]
†
Minimum disease burden is estimated from the combined total of lymphoblasts (CD45+/CD19+ cells) from bone marrow and spleen of untreated animals. Each animal was injected with 1 × 107 cells